PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
<p>Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; updated Phase 1 data expected in 2H 2023 Concluded successful End-of-Phase 1 FDA meeting with alignment on recommended Phase 2 dose and key elements of single arm, Phase […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/pmv-pharmaceuticals-reports-second-quarter-2023-financial-results-and-corporate-highlights/">PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>
Leave a Comment